Drug Trial Radar · NCT01897896
Alternatives for Reducing Chorea in Huntington Disease
Last checked: Nov 20, 2026Latest source record: Nov 9, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
119
Actual
Start
Nov 12, 2013
Primary completion
Aug 21, 2017
Study completion Aug 21, 2017
Sponsor
- Lead sponsor
- Auspex Pharmaceuticals, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jul 12, 2013
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of SD-809 extended release (ER) in participants switching from tetrabenazine to SD-809 ER. In addition, the safety and tolerability of long-term treatment with SD-809 ER will be assessed in "Switch" participants as well as "Rollover" participants completing a randomized, double blind, placebo-controlled study of SD-809 ER.
Conditions
- Chorea Associated With Huntington Disease
Interventions
SD-809Drug
SD-809 tablets will be provided in dose strengths of 6, 9 and 12 mg.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs, Severe TEAEs, Drug-Related TEAEs, and TEAEs Leading to Withdrawal During Entire Treatment PeriodTime frame: Baseline to follow-up visit (up to approximately 3 years 9 months)
- Rollover Cohort: Number of Participants With TEAEs, Serious TEAEs, Severe TEAEs, Drug-Related TEAEs, and TEAEs Leading to Withdrawal During TitrationTime frame: Day 1 to end of Week 8
- Switch Cohort: Number of Participants With TEAEs, Serious TEAEs, Severe TEAEs, Drug-Related TEAEs, and TEAEs Leading to Withdrawal During Dose AdjustmentTime frame: Day 1 to end of Week 4
- Number of Participants With TEAEs, Serious TEAEs, Severe TEAEs, Drug-Related TEAEs, and TEAEs Leading to Withdrawal During Long Term Stable Dose TreatmentTime frame: Week 8 to follow-up visit (up to approximately 3 years 9 months)
Locations
38 sites in 3 countries. Site status is shown where the registry gives one.
Teva Investigational Site 057
Birmingham, Alabama
Teva Investigational Site 038
Phoenix, Arizona
Teva Investigational Site 298
Fayetteville, Arkansas
Teva Investigational Site 052
Englewood, Colorado
Teva Investigational Site 333
Washington D.C., District of Columbia
Teva Investigational Site 160
Gainesville, Florida
Teva Investigational Site 014
Miami, Florida
Teva Investigational Site 032
Atlanta, Georgia
Teva Investigational Site 045
Indianapolis, Indiana
Teva Investigational Site 024
Iowa City, Iowa
Teva Investigational Site 029
Kansas City, Kansas
Teva Investigational Site 083
Wichita, Kansas
Teva Investigational Site 087
Louisville, Kentucky
Teva Investigational Site 028
Baltimore, Maryland
Teva Investigational Site 040
Boston, Massachusetts
Teva Investigational Site 027
St Louis, Missouri
Teva Investigational Site 194
Las Vegas, Nevada
Teva Investigational Site 328
Camden, New Jersey
Teva Investigational Site 026
New Brunswick, New Jersey
Teva Investigational Site 037
Albany, New York
Teva Investigational Site 002
New York, New York
Teva Investigational Site 342
Patchogue, New York
Teva Investigational Site 119
Durham, North Carolina
Teva Investigational Site 089
Cincinnati, Ohio
Teva Investigational Site 020
Columbus, Ohio
Teva Investigational Site 093
Toledo, Ohio
Teva Investigational Site 341
Tulsa, Oklahoma
Teva Investigational Site 031
Nashville, Tennessee
Teva Investigational Site 007
Houston, Texas
Teva Investigational Site 199
Houston, Texas
Teva Investigational Site 100
Salt Lake City, Utah
Teva Investigational Site 137
Burlington, Vermont
Teva Investigational Site 220
Kirkland, Washington
Teva Investigational Site 096
Seattle, Washington
Teva Investigational Site 054
Sydney, Australia
Teva Investigational Site 098
Montreal, Canada
Teva Investigational Site 231
Ottawa, Canada
Teva Investigational Site 300
Toronto, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.